Summary & Overview
CPT 81451: Targeted Genomic Sequence Analysis Panel, Hematolymphoid RNA (5-50 Genes)
CPT code 81451 represents a targeted genomic sequence analysis panel for hematolymphoid neoplasms or disorders, focusing on RNA analysis of 5 to 50 genes. This advanced molecular genetic testing is crucial for the diagnosis and management of complex hematolymphoid diseases, offering clinicians precise genetic information to guide treatment decisions. The code is widely recognized and utilized in laboratory settings, reflecting the growing importance of molecular diagnostics in pathology.
Major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, provide coverage for this procedure, underscoring its clinical relevance and widespread adoption. Readers will gain insights into payer coverage benchmarks, recent policy updates, and the clinical context surrounding the use of 81451. The publication also explores related codes, such as 81445, 81450, 81455, and 81456, to provide a comprehensive overview of targeted genomic testing options for hematolymphoid disorders.
Key topics include the role of molecular genetic testing in pathology, typical laboratory sites of service, and the importance of accurate coding for reimbursement and compliance. This summary equips healthcare professionals, billing specialists, and policy analysts with essential information on the utilization and coverage landscape for 81451, supporting informed decision-making in clinical and administrative settings.
CPT Code Overview
CPT code 81451 is used to report a targeted genomic sequence analysis panel for hematolymphoid neoplasms or disorders, specifically focusing on RNA analysis of 5 to 50 genes. This procedure falls under the Pathology / Molecular Genetic Testing service type and is typically performed in a laboratory setting (Place of Service 81). The test is designed to provide detailed genetic information that can assist in the diagnosis and management of hematolymphoid conditions, supporting clinical decision-making with advanced molecular insights.
Clinical & Coding Specifications
Clinical Context
A patient presents with clinical signs suggestive of a hematolymphoid neoplasm, such as unexplained cytopenias or abnormal blood counts. The treating physician, often a hematologist or oncologist, orders targeted genomic sequence analysis to identify specific RNA mutations across 5-50 genes relevant to hematolymphoid disorders. The specimen is sent to a laboratory (Place of Service 81), where a pathologist or molecular geneticist performs the analysis using CPT code 81451. The results inform diagnosis, prognosis, and potential therapeutic options for conditions like myelodysplastic disease.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component of the service (interpretation and report by the physician). - Modifier
TC: Used when reporting only the technical component (performance of the test in the laboratory).
- Modifier
-
Provider Taxonomies:
Code Specialty Name